http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-111569065-B
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-39558 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-64 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-85 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-64 |
| filingDate | 2020-05-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2023-01-31-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2023-01-31-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-111569065-B |
| titleOfInvention | Composition and application of nanobody targeting ubiquitination to degrade endogenous Survivin in cells |
| abstract | The present invention provides a nanobody-targeted ubiquitination-degradation composition of endogenous Survivin in cells, including Survivin nanobody, Fc domain, T2A polypeptide and TRIM21. The composition is preferably Nb4A-Fc-T2A-TRIM21. The present invention adopts the method of co-expression of nanobody and TRIM21. On the one hand, nanobody can be provided to bind Survivin antigen, Fc fragment to bind TRIM21; TRIM21 can be recruited to maintain the normal progress of ubiquitination. This method achieves the goal of targeting the ubiquitination and degradation of endogenous Survivin in cells, and lays a solid foundation for downstream research on the impact of Survivin degradation on cells, suggesting that it has strong drug application prospects. |
| priorityDate | 2020-05-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 590.